Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Deficit in Insulin-Degrading Enzyme Yields Increased Aβ and Intracellular Domain
30 March 2003. Extending in-vitro evidence that insulin-degrading enzyme (IDE) may be involved in the clearance of the Aβ peptide, a report in the 12 March issue of PNAS finds that IDE knockout mice have higher cerebral accumulation of both Aβ and the AβPP intracellular domain.

An association between AD, hyperinsulinemia, and diabetes has been posited in recent research reports. Epidemiologic studies have linked both type 2 (adult-onset) diabetes mellitus and hyperinsulinemia to an increased risk of AD. Furthermore, there are hints that IDE genotype can affect the risk of developing late-onset Alzheimer's disease (see ARF related news story) and ARF meeting report).

In the present study, researchers at Harvard University and the Mayo Clinic in Jacksonville, Florida, used IDE knockout mice to look at the effects of IDE deficiency on markers of both diabetes and AD. In their first experiment, first author Wesley Farris, with Suzanne Guenette and colleagues, showed that brain homogenates, as well as intact, living neurons from mice lacking IDE, degraded less synthetic Aβ1-40 than did tissue or neurons from IDE wild-type mice. Similar deficits were found in the insulin degradation capacity of the liver of IDE knockout mice.

The researchers then asked whether this meant that IDE knockout mice have higher levels of endogenous Aβ As measured by ELISA, 12-week-old IDE-deficient mice had a 64 percent elevation of cerebral Aβ1-40 compared to wild-type. At six months, IDE-deficient mice had significant elevations of both Aβ1-40 and 1-42, though the Aβ1-40 elevation relative to wild-type had dropped from the 12-week levels.

IDE has also been found to degrade the intracellular domain (AICD) that Aß leaves behind after AβPP is cleaved. AICD has been shown to be transcriptionally active (see ARF related news story), perhaps with a role in apoptosis (see ARF related news story). Farris and colleagues found that levels of AICD were also elevated in brains of IDE knockout mice. Finally, the researchers report that the IDE-deficient mice showed two hallmarks of type 2 diabetes: hyperinsulinemia and glucose intolerance.

In their discussion, the authors offer two hypotheses on apparent links among type 2 diabetes, hyperinsulinemia, and AD. "A primary decrease in IDE function can put an individual at risk for these conditions, as suggested by the genetic evidence for an AD and a DM2 gene in the same IDE-containing region of chromosome 10q. Chronic hyperinsulinemia, whether caused by IDE dysfunction or another mechanism, could provide an avid competitive substrate to IDE, resulting in decreased degradation and resultant gradual accumulation of Aβ" the authors write.-Hakon Heimer.

Reference:
Farris W, Chang Y, Mansourian S, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S. Insulin-degrading enzyme regulates the levels of insulin, amyloid {beta}-protein, and the {beta}-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A. 2003 Mar 12. Abstract

 
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad